CSV vs CSA: Computer System Validation vs Software Assurance Explained

Computer System Validation (CSV) and Computer Software Assurance (CSA) are two fundamentally different approaches to demonstrating that software systems in regulated life sciences environments are fit for their intended use. CSV, the dominant methodology since the late 1990s, relied on exhaustive documentation and scripted testing for every software function regardless of risk. CSA, finalized by the FDA on September 24, 2025, replaces that approach with a risk-based model where the depth of assurance activity scales to the function's impact on patient safety, product quality, and data integrity. For organizations that use electronic signatures and electronic records under FDA 21 CFR Part 11, this shift changes how validation teams plan, execute, and document their qualification activities.

This article explains what CSV is, why it became burdensome, what CSA changes, how the two approaches compare across key dimensions, and what the shift means for teams validating e-signature platforms. It's the conceptual companion to our IQ/OQ/PQ validation guide, which covers the practical execution of qualification protocols under CSA.

What Is Computer System Validation (CSV)?

Computer System Validation is the documented process of establishing, through objective evidence, that a computerized system consistently performs according to predetermined specifications and quality attributes. CSV emerged in the pharmaceutical and medical device industries during the late 1990s and early 2000s as the primary methodology for satisfying FDA expectations under 21 CFR Part 11, 21 CFR Parts 210/211 (cGMP), and 21 CFR Part 820 (Quality System Regulation).

The CSV approach was heavily shaped by GAMP 5 (Good Automated Manufacturing Practice), published by ISPE. GAMP 5 introduced the concept of software categories (from Category 1 infrastructure software through Category 5 custom-built applications) and established the principle that validation effort should scale with system complexity and configurability.

In practice, CSV typically involved the following activities for every regulated computerized system:

• Validation Master Plan defining the scope, strategy, and acceptance criteria
• User Requirement Specification (URS) documenting all functional and regulatory requirements
• Functional Specification (FS) and Design Specification (DS) traceable to the URS
• Risk assessment (often FMEA-based) identifying potential failure modes
• IQ/OQ/PQ protocols with pre-approved, scripted test cases for every function
• Traceability matrix linking requirements to specifications to test cases to test results
• Formal deviation management for any test that did not produce the expected result
• Validation Summary Report documenting the outcome and any residual risks

The Problems with Traditional CSV

CSV served an important purpose in establishing baseline quality expectations for computerized systems, but it developed real problems over two decades of industry practice.

Documentation Became the Goal, Not Quality

CSV evolved into an exercise where the primary deliverable was a documentation package rather than actual assurance that the system worked correctly. Validation teams routinely spent more time writing, reviewing, and approving test scripts than they spent evaluating whether the system protected data integrity and patient safety. A 500-page validation package for a LIMS or e-signature system wasn't unusual, and much of it covered low-risk display fields, navigation menus, and cosmetic formatting with no bearing on regulatory compliance.

Uniform Rigor Regardless of Risk

Under CSV, a scripted test case verifying that a user profile page displays the correct time zone got the same documentation treatment (pre-approved protocol, expected result, actual result, pass/fail determination, reviewer signature) as a test case verifying that an electronic signature enforces two-component identification per Section 11.200. This consumed enormous resources without matching benefit to product quality or patient safety.

Innovation Resistance

The burden of CSV created a strong disincentive to adopt new technology. Organizations delayed software upgrades, avoided cloud migration, and continued using outdated systems because re-validation under CSV was prohibitively expensive and time-consuming. A simple software update could trigger months of re-validation activity, even when the update addressed security vulnerabilities or improved system reliability. This paradoxically made regulated systems less safe over time.

Misallocation of Expertise

CSV's emphasis on scripted testing meant organizations often delegated test execution to junior staff following step-by-step instructions. The tester didn't need to understand the regulatory requirement behind the test; they simply followed the script and recorded the result. This approach missed defects that fell outside the script's scope and failed to use the domain expertise of experienced validation professionals.

What Is Computer Software Assurance (CSA)?

Computer Software Assurance is the FDA's risk-based approach for establishing confidence that software used in regulated environments is fit for its intended use. The FDA finalized the CSA guidance on September 24, 2025, under the title "Computer Software Assurance for Production and Quality System Software." The guidance had been in draft since September 2022 and underwent extensive public comment before finalization.

CSA rests on three core principles:

1. Risk determines effort. The level of assurance activity for any software function should match the risk that function poses to patient safety, product quality, and data integrity. High-risk functions demand thorough, documented testing. Low-risk functions can be verified through lighter-weight methods.
2. Professional judgment over rote execution. CSA expects assurance activities to be performed by people who understand the system's intended use and the regulatory requirements it must satisfy. A knowledgeable tester exercising judgment provides more assurance than a script executor mechanically following steps without understanding why.
3. Multiple testing methods are valid. Scripted testing, unscripted (ad-hoc or exploratory) testing, error-guessing, vendor evidence review, and operational verification are all legitimate assurance methods. The appropriate method depends on the risk level of the function being tested.

Key Differences: CSV vs CSA

The table below summarizes the fundamental differences between the CSV approach that dominated industry practice for decades and the CSA guidance finalized in September 2025:

Why the FDA Made This Change

The FDA's rationale for CSA is documented in the guidance itself and in the preamble addressing public comments. Three factors drove the shift:

Quality Over Paperwork

The FDA recognized that CSV, as practiced by industry, had become a documentation exercise that didn't reliably improve software quality or patient safety. Organizations were investing enormous resources in producing validation documentation while sometimes missing actual defects that affected regulated operations. The CSA guidance explicitly states that extensive documentation of low-risk test cases doesn't improve assurance and shouldn't be required.

Encouraging Technology Adoption

The validation burden under CSV created a perverse incentive to avoid upgrading systems. Organizations running outdated, insecure, or unreliable software chose to maintain the status quo because re-validation costs were prohibitive. The FDA recognized that this was harming product quality and patient safety, the opposite of what validation was supposed to achieve. CSA's risk-scoped approach to change management directly addresses this problem.

Risk Proportionality

The FDA has consistently moved toward risk-based approaches across its regulatory programs. The 2003 Scope and Application guidance for Part 11 already signaled a risk-based enforcement approach. CSA formalizes this principle for software validation specifically, aligning it with the agency's broader quality-by-design and risk management philosophy.

What CSA Means for E-Signature Platforms Specifically

E-signature platforms sit at the intersection of regulatory compliance and operational workflow. Under CSA, the way organizations validate these systems changes in several important ways.

High-Risk Functions Remain Rigorously Tested

The functions that make an e-signature system Part 11 compliant are, by definition, high-risk under CSA. Electronic signature execution (Section 11.50 and 11.200), audit trail generation and immutability (Section 11.10(e)), access control enforcement (Section 11.10(d)), and signature/record linking (Section 11.70) all directly affect the integrity of electronic records and signatures. These functions demand the same thorough, scripted testing that CSV required, and possibly more rigorous testing, because CSA expects testers with genuine domain expertise rather than script executors.

Low-Risk Functions Get Lighter Treatment

Dashboard layout, email notification formatting, user profile display, and document preview rendering are low-risk under CSA. A failure in any of these areas doesn't compromise data integrity or patient safety. Under CSV, organizations would write scripted test cases with pre-approved expected results for all of these. Under CSA, unscripted verification, operational checks, or reliance on vendor testing evidence is sufficient and explicitly encouraged.

Vendor Evidence Reduces Your Burden

CSA explicitly encourages organizations to use vendor-supplied assurance evidence rather than independently re-testing what the vendor has already verified. For SaaS e-signature platforms, this means vendor-provided IQ/OQ documentation, release testing summaries, infrastructure certifications (SOC 2, ISO 27001), and configuration specifications can directly satisfy portions of your qualification requirements. Qualification timelines that took months under CSV can often shrink to weeks under CSA when the vendor provides thorough documentation.

Change Control Becomes More Practical

Under CSV, a minor software update could trigger re-execution of entire OQ/PQ protocols. Under CSA, the change control assessment evaluates which functions are affected, determines the risk level of those functions, and scopes regression testing accordingly. If a vendor release only affects low-risk display functions, the regression testing can be unscripted. If the release modifies signature execution logic, thorough scripted regression testing is required. This risk-scoped approach removes the primary barrier to keeping e-signature systems current and secure.

How to Determine Your Risk Level

CSA's effectiveness depends entirely on a well-executed risk assessment. The guidance outlines how to categorize software functions by risk. For e-signature platforms, the assessment evaluates two dimensions for each function:

1. Impact on data integrity: Could a failure in this function compromise the trustworthiness, completeness, or accuracy of electronic records or signatures? If yes, the function is high-risk.
2. Impact on patient safety: Could a failure ultimately affect patient outcomes, for example by allowing an unauthorized person to approve a batch release or by enabling undetected modification of clinical trial data? If yes, the function is high-risk.

Functions where the answer to both questions is no are low-risk. Functions where either answer is yes are high-risk. Functions with indirect or contingent impacts typically fall into a medium-risk category. The classification should be documented with rationale for each determination; inspectors will ask why a function was classified at a particular level. For a step-by-step methodology for conducting this risk assessment for e-signature systems, including specific function categorizations, see our IQ/OQ/PQ validation guide.

The Role of Vendor Documentation in CSA

One of CSA's most practically important changes is the formal recognition that vendor-supplied documentation can satisfy customer assurance requirements. Under CSV, the prevailing industry practice was to independently test everything regardless of what the vendor had already verified. CSA changes this calculus.

Vendor documentation that can reduce your qualification effort includes:

• IQ/OQ validation support packages: Pre-written protocols and evidence that the platform's core functions operate as specified, tailored to your deployment configuration.
• Release testing summaries: Evidence of the vendor's own testing for each release, documenting what was tested, what passed, and what was resolved before deployment.
• Infrastructure certifications: SOC 2 Type II, ISO 27001, and cloud provider certifications that cover the infrastructure layer you'd otherwise need to qualify independently.
• Configuration specifications: Documentation of default and configurable settings, enabling you to verify that your specific configuration matches the vendor's tested configuration.
• Regulatory compliance mappings: Documentation showing how the platform's features map to specific regulatory requirements (Part 11 sections, Annex 11 clauses, etc.).

The decision to accept vendor evidence should itself be documented and risk-justified. For high-risk functions, you may accept vendor evidence as supplementary but still conduct independent testing. For low-risk functions, vendor evidence alone may provide sufficient assurance.

Common Misconceptions About CSA

As organizations transition from CSV to CSA, several misconceptions have emerged.

"CSA Means Less Validation"

CSA means different validation, not less. For high-risk functions, CSA expects the same or greater rigor than CSV, with the added expectation that testers bring genuine domain expertise. The reduction applies specifically to low-risk functions where CSV's uniform treatment produced documentation without matching assurance value. Organizations that use CSA to justify minimal testing across the board are misapplying the guidance and will face regulatory scrutiny.

"CSA Eliminates Documentation Requirements"

Not quite. CSA reduces documentation for low-risk functions, but high-risk test cases still require scripted protocols, defined acceptance criteria, and formal deviation management. The risk assessment itself must be documented. Unscripted testing still produces a record of what was tested, what was observed, and whether it passed. The total volume decreases, but what remains is more meaningful and risk-focused.

"CSA Only Applies to Medical Device Software"

The CSA guidance was written for production and quality system software under 21 CFR 820.70(i), which is technically a medical device regulation. But the principles of risk-based assurance aren't device-specific. The pharmaceutical, biotech, and clinical research industries have widely adopted CSA as their validation methodology for all GxP systems. Industry organizations including ISPE, PDA, and DIA have published guidance supporting CSA adoption across GxP disciplines. GAMP 5 Second Edition (2022) itself incorporates these same risk-based principles.

"Unscripted Testing Is Informal or Undocumented"

Unscripted testing under CSA isn't ad-hoc clicking around the system with no records. It means the tester doesn't follow a pre-written script with predetermined steps and expected results. Instead, they use domain expertise to explore the function, identify potential failure modes, and verify correct behavior. They document what they tested, how they tested it, what they observed, and the outcome. The test approach is determined at execution time by a knowledgeable tester rather than predetermined in a script.

"You Can Skip Risk Assessment and Just Test Less"

The risk assessment is the foundation of CSA. Without a documented risk assessment that classifies each function and justifies the testing method selected for it, there's no defensible basis for reducing testing scope. An inspector who sees reduced documentation without a supporting risk assessment will view it as inadequate validation, not CSA adoption. The risk assessment isn't optional; it's the document that makes everything else defensible.

Transitioning from CSV to CSA: Practical Steps

Organizations moving from CSV to CSA should approach the transition systematically:

1. Update your validation SOP. Your validation standard operating procedure should formally adopt CSA principles and define how risk assessments drive testing decisions. Reference the FDA guidance document and any supporting industry guidance your organization follows.
2. Train your validation team. CSA requires testers who understand the regulatory requirements behind the system they're testing. Invest in training that covers Part 11 requirements, audit trail expectations, data integrity principles, and the CSA risk-based methodology.
3. Develop a risk assessment template. Create a standardized template for assessing software functions by risk to data integrity and patient safety. Include guidance on classification criteria and testing method selection.
4. Pilot on a new system. Apply CSA to a new system validation rather than attempting to retroactively convert an existing CSV package. This lets the team build competency with the new approach before addressing legacy systems.
5. Engage your vendors. Ask your software vendors about CSA-compatible documentation. Vendors that provide validation support packages, release testing evidence, and regulatory compliance mappings will cut your qualification effort considerably.
6. Document the transition. Maintain a record of when and how your organization adopted CSA, including the rationale, the updated SOP, training records, and the risk assessment methodology. This provides the foundation for any regulatory discussion about your validation approach.

The Bottom Line

The shift from CSV to CSA isn't a relaxation of validation expectations. It's a reorientation. CSV trained the industry to equate validation quality with documentation volume; CSA redefines quality as confidence that a system reliably performs its intended function, with evidence scaled to the risk of failure.

For e-signature platforms, this means rigorous testing of the functions that make Part 11 compliance possible (signature execution, audit trail integrity, access controls, two-component identification, and record immutability) while reducing overhead for display, navigation, and notification features that don't affect data integrity.

Certivo supports the CSA transition by providing full validation documentation, including IQ/OQ protocols, configuration specifications, regulatory compliance mappings, and release testing summaries, that directly reduce qualification effort for GxP-regulated organizations. Explore our compliance documentation for detailed regulatory mapping, or start a free trial to evaluate the platform against your validation requirements.